Drugs.com
JUNE 12, 2025
THURSDAY, June 12, 2025 — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food and Drug Administration (FDA) has approved a monoclonal.
Science Daily: Pharmacology News
JUNE 16, 2025
Psilocybin, the active ingredient in magic mushrooms, might just revolutionize how depression and anxiety are treated in cancer patients. In a groundbreaking trial, a single dose combined with therapy significantly reduced emotional suffering, and these effects often lasted over two years. As follow-up studies expand the research to multiple doses and larger samples, scientists are eyeing a possible new standard of care that merges psychedelics with psychological support.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioPharma Drive: Drug Pricing
JUNE 18, 2025
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.
Covalent Modifiers
JUNE 16, 2025
Dhirendra K. Simanshu, Rui Xu, James P. Stice, Daniel J. Czyzyk, Siyu Feng, John-Paul Denson, Erin Riegler, Yue Yang, Cathy Zhang, Sofia Donovan, Brian P. Smith, Maria Abreu-Blanco, Ming Chen, Cindy Feng, Lijuan Fu, Dana Rabara, Lucy C Young, Marcin Dyba, Wupeng Yan, Ken Lin, Samar Ghorbanpoorvalukolaie, Erik K. Larsen, Wafa Malik, Allison Champagne, Katie Parker, Jin Hyun Ju, Stevan Jeknic, Dominic Esposito, David M.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Collaborative Drug
JUNE 17, 2025
CDD Vault Update (June #2 2025): Bulk Register Sequences with Custom Monomers, Set X-axis Ranges in Plots, Filter AI Bioisostere Suggestions, Inventory Debits from ELN
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Drugs.com
JUNE 11, 2025
WEDNESDAY, June 11, 2025 -- The U.S. Food and Drug Administration has approved Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults.The combination pill is the first and only FDA-approved triple combination.
Science Daily: Pharmacology News
JUNE 2, 2025
A trial of an interactive game that trains people to alter their brain waves has shown promise as a treatment for nerve pain -- offering hope for a new generation of drug-free treatments.
BioPharma Drive: Drug Pricing
JUNE 2, 2025
The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD1 and VEGF, following Merck, and Pfizer into what’s become a competitive development race.
Covalent Modifiers
JUNE 5, 2025
Gibae Kim, R. Justin Grams, and Ku-Lung Hsu Chemical Reviews 2025 DOI: 10.1021/acs.chemrev.5c00001 Targeting intractable proteins remains a key challenge in drug discovery, as these proteins often lack well-defined binding pockets or possess shallow surfaces not readily addressed by traditional drug design. Covalent chemistry has emerged as a powerful solution for accessing protein sites in difficult to ligand regions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Collaborative Drug
JUNE 11, 2025
Compare top scientific data platforms for AI-driven drug discovery. Evaluate CDD Vault, Dotmatics, Benchling & more for chemistry and biologics workflows.
Chemical Biology and Drug Design
JUNE 17, 2025
Flavonoids exhibit significant potential in cancer therapy by inhibiting MMP-2 and MMP-9 activity and expression, primarily through interactions with their active sites and modulation of the MAPK signaling pathway. Our findings highlight key structure-activity relationships, paving the way for flavonoid-based inhibitors as safer alternatives to conventional treatments.
Drugs.com
JUNE 2, 2025
MONDAY, June 2, 2025 Removing fluoride from the U.S. water supply could result in more than 25 million more decayed teeth in children and teenagers within five years, a new study warns.Thats the equivalent of a decayed tooth for 1 of every 3 kid.
Science Daily: Pharmacology News
JUNE 10, 2025
Scientists in Japan have discovered that a natural compound found in a type of ginger called kencur can throw cancer cells into disarray by disrupting how they generate energy. While healthy cells use oxygen to make energy efficiently, cancer cells often rely on a backup method. This ginger-derived molecule doesn t attack that method directly it shuts down the cells' fat-making machinery instead, which surprisingly causes the cells to ramp up their backup system even more.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioPharma Drive: Drug Pricing
JUNE 10, 2025
The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned with Robert F. Kennedy Jr.’s skeptical views, analysts warned.
Covalent Modifiers
JUNE 12, 2025
Tibor Viktor Szalai, Vincenzo di Lorenzo, Nikolett Péczka, Levente M. Mihalovits, László Petri, Qirat F. Ashraf, Elvin D. de Araujo, Viktor Honti, Dávid Bajusz, and György M. Keserű ACS Medicinal Chemistry Letters 2025 16 (6), 991-997 DOI: 10.1021/acsmedchemlett.4c00622 The STAT family of transcription factors are important signaling hubs, with several of them, particularly STAT3, being emerging oncotargets already investigated in clinical trials.
Collaborative Drug
JUNE 12, 2025
Explore new AI+ and curve fitting tools in CDD Vault for structure prediction, docking, and assay analysis. Now available with no setup required.
Chemical Biology and Drug Design
JUNE 11, 2025
We examined the quinolinequinones' ( QQ1- 7 ) effects on cancer cell lines. The most potent compound was QQ1 against ACHN cells with an IC50 value of 1.5 ± 0.16 μM. For better understanding, the effects of QQ1 on apoptosis, cell cycle, and oxidative stress were investigated. QQ1 inhibited ACHN cell proliferation via cell cycle arrest. The host-guest interactions of quinolinequinones were also studied in detail using thorough in silico docking simulations with pharmacokinetic studies.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drugs.com
JUNE 10, 2025
TUESDAY, June 10, 2025 — U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has removed all 17 members of the expert panel that makes U.S. vaccine recommendations. Kennedy made the surprise announcement in an opinion piece.
Science Daily: Pharmacology News
JUNE 11, 2025
Sea cucumbers, long known for cleaning the ocean floor, may also harbor a powerful cancer-fighting secret. Scientists discovered a unique sugar in these marine creatures that can block Sulf-2, an enzyme that cancer cells use to spread. Unlike traditional medications, this compound doesn t cause dangerous blood clotting issues and offers a cleaner, potentially more sustainable way to develop carbohydrate-based drugs if scientists can find a way to synthesize it in the lab.
BioPharma Drive: Drug Pricing
JUNE 11, 2025
The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to help overcome the packaging constraints of current genetic medicines.
Covalent Modifiers
JUNE 17, 2025
Yu Tung Wong, Charles Bell, and Michael C. Willis Chem. Sci., 2025 DOI [link] Covalent inhibitor design is dominated by the use of electrophilic acrylamide warheads. One limitation of acrylamides is that there are limited opportunities to modify their electrophilicity, and hence reactivity, by simple structural changes. Here we show that vinyl sulfonimidamides are effective electophilic groups for reaction with both sulfur- and nitrogen-based biologically relevant nucleophiles.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Collaborative Drug
JUNE 16, 2025
Compare CDD Vault Curves vs GraphPad Prism for drug discovery data analysis. See which tool best fits your workflow for curve fitting and collaboration.
Drug Target Review
JUNE 6, 2025
In recent years, the field of nuclear medicine has undergone a quiet revolution, particularly in its application to oncology. At the forefront of this transformation is Dr Ebrahim Delpassand, a nuclear medicine physician and the driving force behind RadioMedix (RMX), a radiopharmaceutical company focused on developing targeted diagnostics and therapies.
Drugs.com
JUNE 4, 2025
WEDNESDAY, June 4, 2025 A morning cup of coffee might do more than momentarily boost your energy and spirits.Full-test java also appears to help women age more gracefully, a new study says.Middle-aged women who regularly drank caffeinated coffee w.
Science Daily: Pharmacology News
JUNE 14, 2025
A team at Kobe University has created a game-changing resource for autism research: 63 mouse embryonic stem cell lines, each carrying a genetic mutation strongly associated with the disorder. By pairing classic stem cell manipulation with precise CRISPR gene editing, they ve built a standardized platform that mirrors autism-linked genetic conditions in mice.
BioPharma Drive: Drug Pricing
JUNE 18, 2025
A new pilot program announced by FDA Commissioner Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.
Covalent Modifiers
JUNE 9, 2025
Charlotte M. Zammit, Cory M. Nadel, Ying Lin, Sajjan Koirala, Elnaz Ahani, Patrick Ryan Potts, and Daniel K. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801 Androgen-independent prostate cancers, correlated with heightened aggressiveness and poor prognosis, are caused by mutations or deletions in the androgen receptor (AR) or the expression of truncated variants of AR that are constitutively activated.
Collaborative Drug
JUNE 17, 2025
CDD Vault Update (June #2 2025): Bulk Register Sequences with Custom Monomers, Set X-axis Ranges in Plots, Filter AI Bioisostere Suggestions, Inventory Debits from ELN
Broad Institute
JUNE 11, 2025
Broad Institute and Bayer extend their cardiovascular alliance By Leah Eisenstadt June 11, 2025 Breadcrumb Home Broad Institute and Bayer extend their cardiovascular alliance Partnership will continue with renewed focus on developing new cardiovascular therapies. By Broad Communications June 11, 2025 Related news Broad Institute and Bayer expand cardiovascular alliance Broad Institute of MIT and Harvard and Bayer Healthcare expand their partnership to develop therapies for cardiovascular disease
Expert insights. Personalized for you.
289 
Let's personalize your content